Nanoform Finland (OSTO:NANOFS) LT-Debt-to-Total-Asset : 0.07 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nanoform Finland's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.07.

Nanoform Finland's long-term debt to total assets ratio increased from Dec. 2022 (0.06) to Dec. 2023 (0.07). It may suggest that Nanoform Finland is progressively becoming more dependent on debt to grow their business.

Nanoform Finland LT-Debt-to-Total-Asset Historical Data

The historical data trend for Nanoform Finland's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland LT-Debt-to-Total-Asset Chart

Nanoform Finland Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.25

0.08

0.07

0.06

0.07

Nanoform Finland Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.06	0.06	0.06	0.07

Nanoform Finland LT-Debt-to-Total-Asset Calculation

Nanoform Finland's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	58.201	/	874.021
	=	0.07

Nanoform Finland's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	58.201	/	874.021
	=	0.07

Nanoform Finland (OSTO:NANOFS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nanoform Finland LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanoform Finland (OSTO:NANOFS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OSTO:NANOFS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

NANOFH:Finland 4YL:Germany

Address

Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790

Website

https://www.nanoform.com

Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland (OSTO:NANOFS) Headlines

No Headlines